Tomas G Neilan
Overview
Explore the profile of Tomas G Neilan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
234
Citations
7082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Juhasz V, Suero-Abreu G, Neilan T
J Thromb Thrombolysis
. 2025 Mar;
PMID: 40064838
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy since their first approval in 2011. By unleashing the adaptive immune system, non-cardiac and cardiac immune-related adverse events (irAEs) are common and...
2.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
3.
Bonaca M, Lang N, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, et al.
JACC CardioOncol
. 2025 Feb;
7(2):83-95.
PMID: 39967209
The development of novel treatments has improved cancer outcomes but may result in cardiovascular toxicities. Traditional approaches to clinical trial safety evaluation have limitations in their ability to detect signals...
4.
Juhasz V, Quinaglia T, Drobni Z, Heemelaar J, Neuberg D, Han Y, et al.
JACC CardioOncol
. 2025 Feb;
7(2):125-137.
PMID: 39967198
Background: In the STOP-CA (Statins to Prevent the Cardiotoxicity From Anthracyclines) trial, atorvastatin preserved the left ventricular ejection fraction among patients with lymphoma treated with anthracyclines. The protective mechanisms are...
5.
Bhatti A, Patel R, Dani S, Khadke S, Makwana B, Lessey C, et al.
JACC CardioOncol
. 2025 Jan;
6(6):863-875.
PMID: 39801650
Background: Specific cancer treatments can lead to cancer therapy-related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects. Objectives: This study sought to determine whether...
6.
Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N, et al.
JACC CardioOncol
. 2025 Jan;
6(6):815-834.
PMID: 39801647
The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification,...
7.
Keane F, Neilan T, Jimenez R
JACC CardioOncol
. 2025 Jan;
6(6):946-948.
PMID: 39801636
No abstract available.
8.
Chiang C, Song J, Chi K, Chang Y, Xanthavanij N, Chang Y, et al.
Eur J Cancer
. 2024 Dec;
216:115170.
PMID: 39709670
Background: Immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE). Glucagon-like peptide-1 agonists (GLP1a), initially developed for type 2 diabetes mellitus (T2DM), have...
9.
Blum S, Zlotoff D, Smith N, Kernin I, Ramesh S, Zubiri L, et al.
Nature
. 2024 Nov;
636(8041):215-223.
PMID: 39506125
Immune checkpoint inhibitors are widely used anticancer therapies that can cause morbid and potentially fatal immune-related adverse events such as immune-related myocarditis (irMyocarditis). The pathogenesis of irMyocarditis and its relationship...
10.
Langenbach M, Foldyna B, Hadzic I, Langenbach I, Raghu V, Lu M, et al.
Eur Radiol
. 2024 Oct;
PMID: 39480533
Purpose: Medical reports, governed by HIPAA regulations, contain personal health information (PHI), restricting secondary data use. Utilizing natural language processing (NLP) and large language models (LLM), we sought to employ...